These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 2526618)
1. [Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors]. Yanagawa Y; Okazaki T; Okamura S; Ueki M; Sugimoto O Gan To Kagaku Ryoho; 1989 Jul; 16(7):2393-8. PubMed ID: 2526618 [TBL] [Abstract][Full Text] [Related]
2. [Bone marrow suppression in gynecological patients with malignant tumor treated with combination chemotherapy cyclophosphamide, pirarubicin and cisplatin]. Kozaki S; Yanagawa Y; Ueki M; Sugimoto O; Okazaki T; Saeki M; Nomura H; Kanda T; Iwai E; Miyawaki Y Gan To Kagaku Ryoho; 1990 Jun; 17(6):1189-93. PubMed ID: 2350194 [TBL] [Abstract][Full Text] [Related]
3. [Effect of short-term administration of medroxyprogesterone acetate on side reactions of combination chemotherapy with ADR, VDS and CDDP in primary lung cancer]. Suzuki K; Nogimura H; Wada H; Tomii M; Sugimura H; Horiguchi T; Kimura T; Harada Y Gan To Kagaku Ryoho; 1991 Mar; 18(3):431-5. PubMed ID: 1825910 [TBL] [Abstract][Full Text] [Related]
5. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group. Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945 [TBL] [Abstract][Full Text] [Related]
6. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients). Focan C; Baudoux A; Beauduin M; Bunescu U; Dehasque N; Dewasch L; Lobelle JP; Longeval E; Majois F; Salamon E Anticancer Res; 1986; 6(5):1095-9. PubMed ID: 2948442 [TBL] [Abstract][Full Text] [Related]
7. [Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer]. Ushiki N; Jobo T; Shimoda T; Kuramoto H; Arai M Gan To Kagaku Ryoho; 1988 Sep; 15(9):2701-6. PubMed ID: 3415268 [TBL] [Abstract][Full Text] [Related]
8. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
9. [Therapy of advanced endometrial cancer]. Okada H; Yamamoto T Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105 [TBL] [Abstract][Full Text] [Related]
10. [Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma]. Tajima H; Okada T; Fujimori Y; Tomioka Y; Hirano M; Yoshida T; Ikeda S; Hata T Gan To Kagaku Ryoho; 1989 Jul; 16(7):2461-4. PubMed ID: 2526620 [TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors]. Kitada M; Sawaragi I Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476 [TBL] [Abstract][Full Text] [Related]
12. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer. Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173 [TBL] [Abstract][Full Text] [Related]
13. [Disorder of serum electrolytes following CAP therapy]. Matsuura Y; Shinohara M; Kashimura M; Baba S; Otsuka H; Okamura Y Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1635-41. PubMed ID: 1744461 [TBL] [Abstract][Full Text] [Related]
14. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats. Winneker RC; Parsons JA Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344 [TBL] [Abstract][Full Text] [Related]
15. [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide]. Tanase Y; Kawaguchi R; Haruta S; Kanayama S; Yamada Y; Kobayashi H Gan To Kagaku Ryoho; 2006 Jul; 33(7):945-50. PubMed ID: 16835485 [TBL] [Abstract][Full Text] [Related]
16. [Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia]. Asukai K; Kimura A; Gorai I; Uemura T; Minaguchi H Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2583-7. PubMed ID: 2774588 [TBL] [Abstract][Full Text] [Related]
17. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone. Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896 [TBL] [Abstract][Full Text] [Related]
18. Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: relation with hormone sensitivity. Formelli F; Ronchi E; Di Fronzo G Anticancer Res; 1985; 5(3):313-9. PubMed ID: 3160299 [TBL] [Abstract][Full Text] [Related]
19. [Combined therapies with medroxyprogesterone acetate (MPA) in DMBA-induced rat mammary cancer]. Ishikawa H; Iino Y; Izuo M; Takikawa H Gan No Rinsho; 1986 Feb; 32(2):151-5. PubMed ID: 2937941 [TBL] [Abstract][Full Text] [Related]
20. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]